medigraphic.com

2019, Number 1

<< Back Next >>

Cir Cir 2019; 87 (1)

Predictive value of procalcitonin for the need of surgery and the presence of ischemia and necrosis in patients with small bowel obstruction

Evaristo-Méndez G, Gallegos-Sierra C, De La Cruz-Temores S

Language: Spanish
References: 36
Page: 45-52
PDF size: 300.04 Kb.


ABSTRACT

Introduction: The purpose of this prospective cohort study was to evaluate whether serum procalcitonin (PCT) levels predict the need for surgery and the presence of ischemia and/or necrosis (I/N) in small bowel obstruction. Method: Of 54 patients included, conservative management was performed in 31 (non-surgical group) and an exploratory laparotomy in 23 (surgical group). The reference value of the PCT was between 0.10 and 0.50 ng/mL. Results: PCT levels were higher in the surgical group (7.05 ± 7.03 ng/mL) than in the non-surgical (0.37 ± 0.63 ng/mL), and in patients with I/N (10.06 ± 7.07 ng/mL) than without I/N (1.52 ± 1.45 ng/mL). In the ROC curve, the area under the curve was 0.91 for the need for surgery and 0.93 for I/N. PCT ≥ 0.80 ng/mL had the best sensitivity and specificity for surgery and ≥ 1.95 ng/mL for I/N. PCT was also an independent predictor for these events. Conclusions: The levels of PCT can recognize the need for surgery and the presence of I/N in small bowel obstruction. Additional studies are needed to affirm or invalidate our findings.


REFERENCES

  1. Cosse C, Regimbeau JM, Fuks D, Mauvais F, Scotte M. Serum procalcitonin for predicting the failure of conservative management and the need for bowel resection in patients with small bowel obstruction. J Am Coll Surg. 2013;216:997-1004.

  2. Miller G, Boman J, Shrier I, Gordon PH. Natural history of patients with adhesive small bowel obstruction. Br J Surg. 2000;87:1240-7.

  3. Margenthaler JA, Longo WE, Virgo KS, Johnson FE, Grossmann EM, Schifftner TL, et al. Risk factors for adverse outcomes following surgery for small bowel obstruction. Ann Surg. 2006;243:456-64.

  4. Tanaka S, Yamamoto T, Kubota D, Matsuyama M, Uenishi T, Kubo S, et al. Predictive factors for surgical indication in adhesive small bowel obstruction. Am J Surg. 2008;196:23-7.

  5. Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49(Suppl 1):S57-61.

  6. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002;323:17-29.

  7. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010;159:253-64.

  8. Liappis AP, Gibbs KW, Nylen ES, Yoon B, Snider RH, Gao B, et al. Exogenous procalcitonin evokes a pro-inflammatory cytokine response. Inflamm Res. 2011;60:203-7.

  9. Russwurm S, Stonans I, Stonane E, Wiederhold M, Luber A, Zipfel PF, et al. Procalcitonin and CGRP-1 mRNA expression in various human tissues. Shock. 2001;16:109-12.

  10. Araujo M, Doi SQ, Palant CE, Nylen E, Becker KL. Procalcitonin induced cytotoxicity and apoptosis in mesangial cells: implications for septic renal injury. Inflamm Res. 2013;62:887-94.

  11. Nagata J, Kobayashi M, Nishikimi N, Komori K. Serum procalcitonin (PCT) as a negative screening test for colonic ischemia after open abdominal aortic surgery. Eur J Vasc Endovasc Surg. 2008;35:694-7.

  12. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426-35.

  13. Delèvaux I, André M, Colombier M, Albuisson E, Meylheuc F, Bègue RJ, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis. 2003;62:337-40.

  14. Rau BM, Kemppainen EA, Gumbs AA, Büchler MW, Wegscheider K, Bassi C, et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. Ann Surg. 2007;245:745-54.

  15. Takeuchi K, Tsuzuki Y, Ando T, Sekihara M, Hara T, Yoshikawa M, et al. Clinical studies of strangulating small bowel obstruction. Am Surg. 2004;70:40-4.

  16. Lo OS, Law WL, Choi HK, Lee YM, Ho JW, Seto CL. Early outcomes of surgery for small bowel obstruction: analysis of risk factors. Langenbecks Arch Surg. 2007;392:173-8.

  17. Evennett NJ, Petrov MS, Mittal A, Windsor JA. Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia. World J Surg. 2009;33:1374-83.

  18. Rau B, Krüger CM, Schilling MK. Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbecks Arch Surg. 2004;389:134-44.

  19. Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin. 2011;27:253-63.

  20. Rau BM, Frigerio I, Büchler MW, Wegscheider K, Bassi C, Puolakkainen PA, et al. Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study. Arch Surg. 2007;142:134-42.

  21. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79:1605-8.

  22. Connert S, Stremmel W, Elsing C. Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol. 2003;41:165-70.

  23. Karabulut K, Gül M, Dündar ZD, Cander B, Kurban S, Toy H. Diagnostic and prognostic value of procalcitonin and phosphorus in acute mesenteric ischemia. Ulus Travma Acil Cerrahi Derg. 2011;17:193-8.

  24. Ayten R, Dogru O, Camci C, Aygen E, Cetinkaya Z, Akbulut H. Predictive value of procalcitonin for the diagnosis of bowel strangulation. World J Surg. 2005;29:187-9.

  25. Papaziogas B, Anthimidis G, Koutelidakis I, Atmatzidis S, Atmatzidis K. Predictive value of procalcitonin for the diagnosis of bowel strangulation. World J Surg. 2008;32:1566-7.

  26. Maruna P, Fraško R, Gürlich R. Plasma procalcitonin in patients with ileus. Relations to other inflammatory parameters Physiol Res. 2008;57:481-6.

  27. Markogiannakis H, Memos N, Messaris E, Dardamanis D, Larentzakis A, Papanikolaou D, et al. Predictive value of procalcitonin for bowel ischemia and necrosis in bowel obstruction. Surgery. 2011;149:394-403.

  28. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285-93.

  29. Cosse C, Sabbagh C, Kamel S, Galmiche A, Regimbeau JM. Procalcitonin and intestinal ischemia: a review of the literature. World J Gastroenterol. 2014;20:17773-8.

  30. Miller G, Boman J, Shrier I, Gordon PH. Etiology of small bowel obstruction. Am J Surg. 2000;180:33-6.

  31. Cossé C, Sabbagh C, Carroni V, Galmiche A, Rebibo L, Regimbeau JM. Impact of a procalcitonin-based algorithm on the management of adhesion- related small bowel obstruction. J Visc Surg. 2017;154:231-7.

  32. Fevang BT, Fevang J, Stangeland L, Soreide O, Svanes K, Viste A. Complications and death after surgical treatment of small bowel obstruction: a 35-year institutional experience. Ann Surg. 2000;231 529-37.

  33. Van Leeuwen PA, Boermeester MA, Houdijk AP, Ferwerda CC, Cuesta MA, Meyer S, et al. Clinical significance of translocation. Gut. 1994;35(1 Suppl):S28-34.

  34. Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89:1512-25.

  35. Soybel DI, Zinner MJ. Ileus and the macrophage. Ann Surg. 2003;237:316-8.

  36. Wehner S, Schwarz NT, Hundsdoerfer R, Hierholzer C, Tweardy DJ, Billiar TR, et al. Induction of IL-6 within the rodent intestinal muscularis after intestinal surgical stress. Surgery. 2005;137:436-46.




2020     |     www.medigraphic.com